Twenty years of research has finally borne fruit. Scientists have developed for the first time an experimental drug that can repair DNA and promote the regeneration of damaged tissue, opening up new ways to treat myocardial infarction, inflammatory diseases and other conditions that cause tissue damage. This drug candidate, called TY1, gives damaged myocardium and other tissues the opportunity to "self-repair" at a fundamental level by enhancing the body's own DNA repair ability. It is regarded by the research team as the beginning of "a completely new drug category."
This work was led by a research team at Cedars-Sinai Medical Center in the United States. The breakthrough originated from the isolation and research of cardiac precursor cells in the early years. Scientists have discovered that this type of stem cell-like cardiac precursor cells can not only differentiate into new healthy heart muscle tissue, but also release vesicles carrying DNA, RNA and protein molecules - "exosomes". These "micro-messengers" shuttle between cells and have the remarkable ability to repair and regenerate damaged tissue. The team then sequenced and screened the RNA components in exosomes, and finally identified one of the RNA molecules that plays a particularly critical role in the repair process, and confirmed its core function in tissue repair in animal models.
On this basis, the researchers synthesized an artificial version of this natural "healing molecule" in the laboratory, namely TY1, and proposed the new concept of "exosome-derived drugs (exomers)". TY1 is structurally similar to some existing RNA drugs, and its mechanism of action is to enhance the activity of the Trex1 gene, thereby improving the efficiency of immune cells involved in clearing damaged DNA, allowing "cell scavengers" to remove damaged fragments faster, creating conditions for subsequent repair and regeneration. After myocardial infarction, this process helps reduce scarring of cardiac tissue and improves long-term cardiac function prognosis, and is therefore considered to have potential significance in a variety of cardiovascular diseases such as heart failure, dilated cardiomyopathy, and age-related cardiac injury.
The research team pointed out that DNA damage plays a key role in stress heart failure, dilated cardiomyopathy and cardiac aging. The more damaged myocardium, the worse the patient's long-term prognosis is usually. Activating the "recovery team" at the cellular level through TY1 strengthens DNA repair and tissue regeneration, which may help the body retain more functional myocardium after acute cardiac events. What’s more promising is that this mechanism is not limited to the heart: in some autoimmune diseases, the body’s immune system mistakenly attacks healthy tissue, and the performance of TY1 in relevant animal models shows that it is expected to reduce this type of chronic inflammatory damage by improving DNA repair and cellular environment.
At present, TY1 has completed preliminary animal studies and will enter the clinical trial stage to evaluate its safety and effectiveness in humans. If the trial results are as expected, this first-of-its-kind "exosome-derived RNA drug" has the potential to develop into a new class of therapeutic tools to deal with the widespread cell and tissue damage caused by heart attacks, long-term inflammation, and a variety of chronic diseases. Relevant research papers have been published in Science Translational Medicine, marking a new milestone in the research and development of precision drugs targeting DNA damage and tissue regeneration.